ABBV-951 Found to Help Control Motor Symptoms in Phase 3 Trial
ABBV-951, a continuous infusion formulation of levodopa/carbidopa that’s administered under the skin, improved “on” time and decreased “off” time when compared with standard oral therapy in people with advanced Parkinson’s disease. Those are the results of a randomized Phase 3 clinical trial testing the experimental formulation in more than…